{
    "id": 26846,
    "cites": 15,
    "cited_by": 1,
    "reference": [
        "Baily, Martin Neil, David Campbell Charles Hulten, Timothy Bresnahan, and Richard E. Caves. 1991. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Productivity Dynamics in Manufacturing Plants.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Brookings papers on economic activity, Microeconomics, 1992.",
        "Chandra, Amitabh, Amy Finkelstein, Adam Sacarny, and Chad Syverson. 2016. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health Care Exceptionalism? Performance and Allocation in the US Health Care Sector.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 106(8).",
        "Dabora, Matan C., Namrata Turaga, and Kevin A. Schulman. 2017. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Financing and Distribution of Pharmaceuticals in the United States.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d JAMA, 317(1).",
        "Dafny, Leemore, Christopher Ody, and Matthew Schmidt. 2017. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093When Discounts Raise Costs: the Effect of Copay Coupons on Generic Utilization.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Journal: Economic Policy, 9(2).",
        "Foster, Lucia, John C. Haltiwanger, and Cornell John Krizan. 2001. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Aggregate Productivity Growth: Lessons from Microeconomic Evidence.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d In New developments in productivity analysis. University of Chicago Press.",
        "Foster, Lucia, John Haltiwanger, and Chad Syverson. 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Reallocation, Firm Turnover, and Efficiency: Selection on Productivity or Profitability?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 98(1).",
        "Gellad, Walid F., Sebastian Schneeweiss, Phyllis Brawarsky, Stuart Lipsitz, and Jennifer S. Haas. 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093What if the Federal Government Negotiated Pharmaceutical Prices for Seniors? an Estimate of National Savings.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of General Internal Medicine, 23(9).",
        "Hartung, Daniel M., Dennis N. Bourdette, Sharia M. Ahmed, and Ruth H. Whitham. 2015. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Cost of Multiple Sclerosis Drugs in the US and the Pharmaceutical Industry: Too Big to Fail?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Neurology, 84(21).",
        "Health Care Cost Institute. 2017. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u00932017 Health Care Cost and Utilization Report.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Care Cost Institute. 2018. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Understanding How Price Growth Affected Areas Differently Across the Country.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Herkert, Darby, Pavithra Vijayakumar, Jing Luo, Jeremy I. Schwartz, Tracy L. Rabin, Eunice DeFilippo, and Kasia J. Lipska. 2019. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Cost-related Insulin Underuse Among Patients with Diabetes.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d JAMA internal medicine, 179(1).",
        "Hernandez, Inmaculada, Alvaro San-Juan-Rodriguez, Chester B. Good, and Walid F. Gellad. 2020. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d JAMA, 323(9).",
        "Hernandez, Inmaculada, Chester B. Good, David M. Cutler, Walid F. Gellad, Natasha Parekh, and William H. Shrank. 2019. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Contribution of New Product Entry Versus Existing Product Inflation in the Rising Costs of Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Ho, Kate, and Robin S. Lee. 2017. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Insurer Competition in Health Care Markets.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Econometrica, 85(2).",
        "IQVIA Institute. 2018. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicine Use and Spending in the US: a Review of 2017 and Outlook to 2022.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Kesselheim, Aaron S, Bo Wang, Jessica M Franklin, and Jonathan J Darrow. 2015.",
        "\u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Trends in Utilization of FDA Expedited Drug Development and Approval Programs, 1987-2014: Cohort Study.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Bmj, 351.",
        "Long, Doug. 2018. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Global Generic and Biosimilar Trends and Insights.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Sarpatwari, Ameet, Jonathan DiBellow, Marie Zakarian, Mehdi Najafzadeh, and Aaron S. Kesselheim. 2019. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Competition and Price Among Brand-name Drugs in the Same Class: A Systematic Review of the Evidence.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Plos medicine, 16(7).",
        "Sood, Neeraj, Rocio Ribiero, Martha Ryan, and Karen Van Nuys. 2020. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Association Between Drug Rebates and List Prices (White paper).\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Leonard D. Schaffer Center for Health Economics Policy."
    ]
}